# US 2026/0062401 A1 · Methods of treating neurological disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062401 A1
- Document ID: US20260062401A1
- Status: Published application
- Kind: A1
- Application number: 19/249,829
- Filed: 2025-06-25
- Published: 2026-03-05
- Earliest claimed: 2022-12-02
- Assignees: Neumora Therapeutics, Inc.
- Applicants: Neumora Therapeutics, Inc.
- Inventors: Paul Dransfield; Dilinie Fernando; James Harvey; Brian Sparling; John Stellwagen; Zhihua Ma; Anne-Marie Beausoleil; Ryan Hudson
- Web page: https://patentgrep.com/patent/US20260062401A1

## CPC

- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61P 25/02: for peripheral neuropathies
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein the variable are as described herein, and compositions and uses of same for treating neurological disorders.

## Claims

### Claim 1

A compound of Formula (I),
or a pharmaceutically acceptable salt thereof, wherein:
R1 is hydrogen or C1-C6 alkyl;
R2 is C1-C8 alkyl, C1-C8 haloalkyl, C3-C8 cycloalkyl, or —NRARB;
RA and RB are independently hydrogen or C1-C6 alkyl, or RA and RB together with the nitrogen atom to which they are attached form a 4-6 membered heterocyclyl;
each R3 is independently halogen, cyano, hydroxyl, or C1-C6 alkyl;
X is CH, CR3, or N;
R4 is chloro, cyano, hydroxyl, or trifluoromethyl;
each R5 is independently halogen, cyano, hydroxyl, C1-C6 alkyl, or C1-C6 haloalkyl; and
m and n are independently 0, 1, 2, or 3.

### Claim 2 (depends on 1)

The compound or salt of claim 1, wherein R1 is C1-C6 alkyl.

### Claim 3 (depends on 1)

The compound or salt of claim 1, wherein R1 is hydrogen.

### Claim 4 (depends on 1)

The compound or salt of claim 1, wherein R2 is C1-C8 alkyl.

### Claim 5 (depends on 1)

The compound or salt of claim 1, wherein R2 is isobutyl.

### Claim 6 (depends on 1)

The compound or salt of claim 1, wherein R2 is —NRARB.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The compound or salt of claim 1, wherein RA is methyl.

### Claim at position 9

-11. (canceled)

### Claim 12 (depends on 1)

The compound or salt of claim 1, wherein RB is hydrogen.

### Claim 13 (depends on 1)

The compound or salt of claim 1, wherein m is 1.

### Claim at position 12

-17. (canceled)

### Claim 18 (depends on 1)

The compound or salt of claim 1 and, wherein R3 is methyl.

### Claim 19 (depends on 1)

The compound or salt of claim 1, wherein m is 0.

### Claim 20 (depends on 1)

The compound or salt of claim 1, wherein X is N.

### Claim 21 (depends on 1)

The compound or salt of claim 1, wherein R4 is chloro.

### Claim 22 (depends on 1)

The compound or salt of claim 1, wherein n is 1.

### Claim at position 18

-24. (canceled)

### Claim 25 (depends on 1)

The compound or salt of claim 1, wherein R5 is fluoro.

### Claim 26 (depends on 1)

The compound or salt of claim 1, wherein n is 0.

### Claim 27

(canceled)

### Claim 28 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

### Claim 29 (depends on 1)

A method of treating a CK-1δ-associated neurological disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 30 (depends on 29)

The method of claim 29, wherein the CK-1δ-associated neurological disorder is amyotrophic lateral sclerosis (ALS), Alzheimer's disease, frontotemporal dementia (FTD), frontotemporal lobar degeneration with ubiquitin inclusions (FTLD-U), or limbic-predominant age-related TDP-43 encephalopathy (LATE).
